Sustained reductions in migraine headache days were observed over 24 months, supporting treatment effectiveness.
The reduction in migraine headache days reached significance during treatment analysis, emphasizing clinical impact.
Observational analysis reported long-term effectiveness of anti-CGRP monoclonal antibodies in migraine management.
These results support the need for ongoing evaluation of treatment options for migraines and their persistence factors.
Abstract
This study provides Class IV evidence that, in patients with migraine, treatment with anti-CGRP MAbs is associated with sustained reductions in MHDs over a 24-month period.